Please use this identifier to cite or link to this item:
Title: (-)-Epigallocatechin gallate derivatives for inhibiting proteasome
Authors: Chan, TH 
Lam, WH
Chow, LMC 
Dou, QP
Kuhn, DJ
Kazi, A
Keywords: Catechin
Anticancer agent
Issue Date: 9-Jun-2009
Source: US Patent 7,544,816 B2. Washington, DC: US Patent and Trademark Office, 2009. How to cite?
Abstract: (-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R₁ is selected from the group of --H and C₁ to C[sub 6] acyl group; R₂, R₃, and R₄ are each independently selected from the group of --H, --OH, and C₁ to C[sub 6] acyloxyl group; and at least one of R₂, R₃, or R₄ is --H. The derivatives of (-)-EGCG that is at least as potent as (-)-EGCG. The carboxylate protected forms of (-)-EGCG and its derivatives are found to be more stable than the unprotected forms, which can be used as proteasome inhibitors to reduce tumor cell growth.
Rights: Assignee: The Hong Kong Polytechnic University.
Assignee: Wayne State University.
Assignee: University of South Florida.
Assignee: McGill University.
Appears in Collections:Patent

Files in This Item:
File Description SizeFormat 
us7544816b2.pdf1.26 MBAdobe PDFView/Open
Show full item record
PIRA download icon_1.1View/Download Contents

Page view(s)

Last Week
Last month
Citations as of Sep 16, 2018


Citations as of Sep 16, 2018

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.